Figure 1.
Disease-free survival (DFS) from complete response (CR) for four prognostic cytogenetic risk groups—EORTC/GIMEMA trial comparing sibling allogeneic versus autologous HCT for consolidation.
The cytogenetic risk groups are good risk (1A), normal (1B) and bad/very bad risk (1C). 1D captures the data for patients in whom cytogenetics were unknown. Reprinted with permission from Blood. 2003;102,1237.
